Depression Treatment Shows Early Promise, but Longer Therapy May Be Necessary
Major depression is among the leading causes of disability worldwide, impacting thoughts, emotions, sleep patterns, productivity, and overall enjoyment of life. While many individuals find relief through antidepressant medications and psychotherapy, a significant number continue to experience symptoms despite trying various treatments. This has led researchers to explore alternative approaches that operate differently.
One such emerging treatment gaining attention is intermittent theta-burst stimulation (iTBS). This non-invasive brain stimulation technique uses magnetic pulses to target specific regions of the brain that are involved in mood regulation. Unlike surgery, it requires no incisions or implants. The procedure is performed while the patient remains awake, and each session lasts just a few minutes. The U.S. Food and Drug Administration approved iTBS for clinical use in 2018.
A recent study published in JAMA Network Open investigated whether a standard regimen of once-daily iTBS could more effectively alleviate depression symptoms compared to a placebo. The study involved 73 adults aged 22 to 65 diagnosed with major depressive disorder. Participants were randomly assigned to receive either genuine iTBS or a sham treatment designed to mimic the real procedure in appearance, sound, and sensation but without delivering real brain stimulation.
Each participant underwent one session over ten weekdays. Researchers evaluated depression severity before treatment, midway through, after the tenth session, and four weeks later. Assessments included established depression rating scales completed by both clinicians and patients, along with brain imaging.
Initial results were promising. After just five sessions, patients receiving real iTBS showed more significant improvement than those in the placebo group. By the end of the treatment course, doctor-assessed depression scores had decreased by approximately 42% in the iTBS group, compared to about 22% in the placebo group.
However, these improvements did not fully persist over time. Four weeks after treatment, the placebo group continued to improve, narrowing the gap between the two groups to the point that differences were no longer statistically significant. Interestingly, patient self-reports indicated similar symptom reductions in both groups throughout the study.
These findings suggest that while iTBS can deliver rapid relief for some patients, a ten-session course may not be sufficient for sustained benefits. Longer treatment periods or maintenance sessions might be necessary to maintain the improvements.
If mental health concerns resonate with you, it’s worth exploring studies indicating that a vegetarian diet might raise depression risk, whereas increasing vitamin D intake could help alleviate symptoms.
For additional health-related insights, consider recent research demonstrating why pizza can be highly addictive or how following the MIND diet could support cognitive health in older adults.
Source: JAMA Network Open study.